RXi Pharmaceuticals to Present at the 23rd World Congress of Dermatology

RXi Pharmaceuticals Corporation

, a biotechnology company focused on discovering and developing innovative therapies primarily in the areas of dermatology and ophthalmology, today announced that Dr. Pamela Pavco, RXi's Chief Development Officer, will present at the 23rd World Congress of Dermatology (WCD).  This six-day world congress will include in-depth presentations by world-class clinicians and/or investigators, dermatology forums for health professionals, patient advocacy and support forums and other plenary sessions. Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO On Tuesday, June 9, 2015 at 2:35 p.m. PDT, Dr. Pavco will present an overview of the Company's dermal clinical program with RXI-109. The presentation, entitled "Update on Phase 2a Clinical Trial Results of RXI-109 Treatment to Reduce the Formation of Hypertrophic Dermal Scars and Keloids," will take place during the Free Communications session: FC-07 Wound Healing.  The presentation will be available on the Company's website at www.rxipharma.com approximately one hour after the presentation. About the World Congress of Dermatology The WCD is the world's oldest and continuous international dermatology meeting. The first Congress in 1889 pre-dated the modern Olympics by seven years. This six-day interactive conference includes plenaries, ILDS National and Affiliate society meetings, dermatology forums for health professionals and patient advocacy and